Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intismeran autogene · 6 trials · 8 indications
DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.
RFS is defined as the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause.
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.
OS, defined as the time from randomization to death due to any cause. OS will be presented.
PFS is defined as the time from randomization to the first documented disease progression per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by investigator assessment or death due to any cause, whichever occurs first. Progressive disease (PD) is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS per RECIST 1.1 as assessed by investigator will be presented.
EFS is defined as the time from randomization to any of the following events, as determined by blinded independent central review (BICR): High-grade (HG) non-invasive papillary carcinoma (Ta) or carcinoma in situ (CIS) in the bladder at the 24-week assessment or later; Any T1 stage disease in the bladder; Any T2 stage or greater in the bladder, including transurethral prostate stromal invasion of urothelial carcinoma (UC); High-risk disease (defined as HG Ta, CIS, ≥T1) of the urethra or upper tract (ureters, renal pelvis); Metastatic UC \[defined as regional lymph node metastasis of UC (stage N1 or greater), or distant metastasis of UC including non-regional lymph nodes (stage M1)\]; Or death due to any cause. The EFS for BCG-treated participants will be presented.
DFS, as assessed by the investigator, is defined as the time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es), or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Intismeran autogene + Pembrolizumab | EXPERIMENTAL | Participants will receive 1 mg of intismeran autogene via intramuscular (IM) injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via intravenous (IV) infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner. |
| Placebo + Pembrolizumab | ACTIVE_COMPARATOR | Participants will receive intismeran autogene-matched placebo via IM injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via IV infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner. |
| Intismeran Autogene + Pembrolizumab + Chemo | EXPERIMENTAL | Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m\^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m\^2 IV infusion weekly × 6 doses). Intismeran Autogene 1 mg intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses. Maintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Intismeran Autogene 1 mg IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance. |
| Placebo + Pembrolizumab + Chemo | EXPERIMENTAL | Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m\^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m\^2 IV infusion weekly × 6 doses). Placebo intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses. Maintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Placebo IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance. |
| Intismeran autogene + BCG | EXPERIMENTAL | Participants in Cohort A receive 1 mg of intismeran autogene via intramuscular (IM) injection every 3 weeks (Q3W) for 9 doses. Participants also receive 50 mg of TICE® BCG once weekly for 6 weeks, then once weekly on weeks 13-15, 25-27, 49-51, and 73-75. |
| BCG | ACTIVE_COMPARATOR | Participants in Cohort A receive 50 mg of TICE® BCG once weekly for 6 weeks, then once weekly on weeks 13-15, 25-27, 49-51, and 73-75 |
| Intismeran autogene | EXPERIMENTAL | Participants in Cohort B receive 1 mg of intismeran autogene via intramuscular (IM) injection every 3 weeks (Q3W) for 9 doses. |
| Name | Type | Description |
|---|---|---|
| Intismeran autogene | BIOLOGICAL | IM injection |
| Pembrolizumab | BIOLOGICAL | IV infusion |
| Placebo | OTHER | IM injection |
| Carboplatin | DRUG | Area Under the Curve (AUC) either 6 or 5 (mg/mL/min) IV Infusion |
| Paclitaxel | DRUG | 200 or 175 mg/m\^2 IV Infusion |
| Nab-paclitaxel | DRUG | 100 mg/m\^2 IV Infusion |
| BCG | BIOLOGICAL | Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin. |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has undergone margin negative, completely resected non-small cell lung cancer (NSCLC), and has pathological Stage II, IIIA, IIIB (N2) squamous or nonsquamous tumor, node, metastasis (TNM) staging per Am...
Top 20 of 50 competitors
Intismeran Autogene is an investigational oncology therapy being studied for malignant melanoma, melanoma, urinary bladder neoplasms, non-small cell lung cancer, renal cell carcinoma, and squamous non-small cell lung cancer. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Intismeran Autogene is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting multiple Phase 2 clinical trials evaluating the drug across several cancer indications, including melanoma, bladder cancer, and lung cancer.
Intismeran Autogene is in Phase 2 clinical development. It is an investigational drug and has not received regulatory approval. The ongoing trials are evaluating its safety and efficacy in various cancer types, including renal cell carcinoma, bladder cancer, melanoma, and non-small cell lung cancer.
Intismeran Autogene is being studied in four Phase 2 trials: NCT06307431 in renal cell carcinoma, NCT06833073 in bladder cancer, NCT06961006 in melanoma, and NCT07221474 in squamous non-small cell lung cancer. These trials are actively recruiting or active but not recruiting participants.
Yes, Intismeran Autogene is also known as V940. Clinical trial titles refer to it as Intismeran Autogene (V940), and it is being studied in combination with other therapies such as pembrolizumab and BCG across multiple cancer indications.